Canexia Health

info@canexiahealth.com
www.canexiahealth.com

Access to Cancer Testing and Treatment

The Access to Cancer Testing and Treatment program, also known as **Project ACTT**, provides high quality cancer genomic testing to patients with metastatic or recurrent lung, breast, or colorectal cancer. Formerly known as **Canadian Early Access Program**, **Canexia Health** initially launched the program in 2019 to provide oncologists and patients with access to a **blood-based,multiplex hotspot mutation panel** known as **Follow It**, using next-generation sequencing (NGS).

Follow It®

Follow It is a clinically actionable, blood-based circulating tumour DNA (ctDNA) NGS multiplex panel that tests for 146 hotspots and 23 exons in 30 cancer genes that are known to be important in the prognosis and treatment of multiple solid adult tumours. Follow It provides a detailed clinical report, which includes interpretations of results, available clinical trials, and current treatment options based on the molecular profile of the tumour.

Benefits To Your Patients

- Minimally invasive sample collection.
- Rapid, actionable results.

Benefits To Your Practice

- Rapid turnaround time for patient treatment information.
- Identification of targeted therapies for your patient, and potentially avoiding treatments that might not be clinically beneficial.

Follow It® Clinical Report:



Canexia Health

Follow It® Report

Patient Name:
Report ID: 544

Date of Birth:
Surgical ID:

Patient ID: pt-DNA-10599-CG001QV40Run26-22
Panel: Full

PATIENT INFORMATION

Patient Name: Jane Doe
Date of Birth: 11/05/1957 Sex: Female
Care Card #: 010101 Province of issue: BC
Diagnosis: None
Reason for Referral: Diagnostic Evaluation
Previous Molecular Tests: N/A
Test Requested: FOLLOW IT
Date of Receipt: None
Date of Report: 2019-08-02 11:41:22

HEALTHCARE PROVIDER INFORMATION

Referring Physician: Nathaneal Down
Institution: ABC General Hospital
Address:
Phone: (999) 000-999 Fax:
Pathologist: Nigel Nigel
Institution: ABC General Hospital
Address:
Phone: (999) 000-999 Fax:

SPECIMEN INFORMATION

Specimen Collection Date: None
Specimen Source: Blood
Specimen Type: Plasma
Primary Site of Tumour: Endometrium
Histologic Type: Endometrioid carcinoma
Sample: DNA-10599-CG001QV40Run26-22

This test is an amplicon based hotspot next-generation sequencing assay (NGS) that interrogates clinically actionable gene alteration incirculation tumour DNA extracted from plasma. The test results, interpretations and clinical trials included in this report are provided in thecontext of a primary cancer type as reported by the referring physician.

CONSIDERATIONS

- POLE mutations are associated with an ultra-mutated tumour phenotype and an excellent prognosis in endometrioid endometrial carcinoma.
- May respond to immunotherapy in the rare recurrent/metastatic setting.
- PIK3CA and PTEN mutations. In the context of POLE-mutated endometrioid endometrial carcinoma, PIK3CA and PTEN mutations are considered secondary events and are not currently associated with prognostic or therapeutic significance.

SUMMARY OF TEST RESULTS

Key Mutations Present*

Gene	cDNA change	Amino Acid Change	Exon	Allelic Ratio (%)	Therapeutic Implication	Level of Evidence	Clinical Trials Available
POLE	c.1251G>T (NM_006231.3)	V411L	13	19.4	Associated with an excellent prognosis in endometrioid endometrial carcinoma.	Tier: II.D • Literature	0
					May respond to immunotherapy in the rarerecurrent/metastatic setting	Tier: II.D • Literature	
PIK3CA	c.263G>A (NM_006218.3)	R88Q	2	28.1	Alterations in PIK3CA are frequent (70%) in POLE- mutated endometrial carcinoma are considered secondary events and are not currently associated with prognostic or therapeutic significance.	Tier: II.D • Literature	0
PTEN	c.389G>A (NM_000314.4)	R130Q	5	24.9	Alterations in PTEN are frequent (94%) in POLE- mutated endometrial carcinoma and are considered secondary events and are not currently associated with prognostic or therapeutic significance.	Tier: II.D • Literature	0
TP53	c.658G>A (NM_000546.5)	R213Q	6	3.1	NA (see other findings section)	NA	NA

TABLE 1: Mutations Present

Important Information about ACTT

Tumor Types Tested	• Breast cancer • Lung cancer • Colorectal cancer
Eligible Patient Population	• Patients with suspected or known relapsed disease where ctDNA testing can detect resistance mutations. • Patients with metastatic disease where ctDNA testing can detect resistance mutations. • Patients with tumour not easily amenable to biopsy. • Very ill patients with metastatic disease.
Turnaround Time	10 working days
Specimen Type	Blood
Specimen Collection	• BC, Ontario, and Saskatchewan patients will take their TRF provided by the referring oncologist to a LifeLabs location, • Quebec Patients will contact Genolife at 1-844-440-5454 to provide their TRF and schedule an appointment at a Genolife sample collection clinic.
Pricing	Testing is available at NO COST for 2000 patients till March 31st, 2021
Further Information	If you would like further information, please send us an email test@canexiahealth.com

About Canexia Health

Canexia Health (formerly Contextual Genomics) makes high-quality cancer genomic information accessible with our clinically-validated assays, informatics, and support. Our suite of genomics-based cancer tests is clinical actionable and cost-effective, designed to improve cancer treatment and monitoring. With our extensive scientific experience, specialized genomics-based tests, and support from pharmaceutical and diagnostics partners, we are leading the shift towards precision oncology.

Suite 204 - 2389 Health Sciences Mall
Vancouver, BC, Canada V6T 1Z3

www.canexiahealth.com

Canexia Health

Genes And Associated Cancer Types

Gene	Therapeutic Options
AKT1	●
ALK	● ● ● ●
AR	● ●
BRAF	● ● ● ●
CTNNB1	●
DDR2	● ● ●
EGFR	● ● ● ●
ERBB2	● ● ●
ESR1	● ●
GNA11	●
GNAQ	●
GNAS	●
HRAS	● ●
IDH1	●
IDH2	●

Gene	Therapeutic Options
KIT	● ● ● ●
KRAS	● ● ● ●
MAP2K1(MEK1)	● ● ●
MAP2K2(MEK2)	● ● ●
MET	● ● ●
NRAS	● ● ● ●
PDGFRA	● ● ●
PIK3CA	● ● ● ●
POLE	●
PTCH1	● ● ●
PTEN	● ● ●
RET	● ● ● ●
ROS1	● ●
SMO	● ●
TP53	

Cancer	Associated Genes
Breast	AKT1,ERBB2, ESR1, PIK3CA
Colorectal	BRAF, KRAS, NRAS, PIK3CA
Endometrial	CTNNB1, PIK3CA, POLE
Melanoma	BRAF, KIT, NRAS
GIST	BRAF, PDGFRA, KIT
Glioma	BRAF, IDH1, IDH2
NSCLC	BRAF, EGFR, ERBB2, KRAS, MET
Sarcoma	GNAS, IDH1, IDH2

Key	Health Canada Approved Drugs	Off-Label Drugs	Clinical Trial	Resistance
	●	●	●	●

CAP ACCREDITED College of American Pathologists · Diagnostic Accreditation Program · CLIA Clinical Laboratory Improvement Amendments